<DOC>
	<DOCNO>NCT00268762</DOCNO>
	<brief_summary>Is combination low dose argatroban combination rt-PA safe , increase recanalization patient acute ischemic stroke .</brief_summary>
	<brief_title>Argatroban Stroke Treatment - A Pilot Safety Study</brief_title>
	<detailed_description>All patient acute ischemic stroke qualify IV rt-PA accept guideline , occlude middle cerebral artery document TCD , receive standard dose IV rt-PA bolus 48 hour infusion argatroban aim prolong aPTT 1.75 X baseline . Follow CT scan TCD every 30 minute 2 hour daily determine incidence hemorrhage , recanalization reocclusion , serial neurological exam determine clinical outcome . For patient without temporal window , baseline CT-Angiogram ( CTA ) demonstrate arterial occlusion also enrol . In patient , follow-up CTA ( 24-36 hour ) perform .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<criteria>Ischemic stroke symptom onset ≤ 3 hours* . *or &lt; 4.5 hour accord local standard care . Symptoms must distinguish another ischemic event syncope , seizure , migraine , hypoglycemia . If patient report awaken event , time onset consider last time patient ( witness patient 's condition ) consider herself/himself normal . 1885 year age . A clot cause complete partial occlusion ( TIBI 0 , 1 , 2 , 3 ) via TCD one follow area : distal iternal carotid artery ( ICA ) , Meddle cerebral artery ( MCA M1 M2 ) , posterior cerebral arteral ( ICA P1 P2 ) , distal vertebral basilar occlusion . TCD must abnormal prior start Argatroban . For patient without temporal window ( center without emergent access TCD ) , abnormal CTA require enrollment ( TIMI 0 1 ) . Females childbearing potential must negative serum pregnancy test prior administration argatroban . Signed informed consent patient patient 's legal representative . Meet criterion rtPA therapy . Evidence intracranial hemorrhage baseline CT scan nonvascular cause neurologic deficit . National institute health stroke scale ( NIHSS ) Level Consciousness score ≥2 . Baseline ( immediately preArgatroban ) NIHSS ≤ 5 patient rapidly resolve deficit rapidly improve symptom consistent TPA . Baseline NIHSS ≥15 right hemisphere stroke ≥20 leave hemisphere stroke . Preexisting disability modify rankin scale ( mRS ) ≥ 2 . CT scan finding hypoattenuation xray signal ( hypodensity ) involve ≥ 1/2 MCA territory . Any evidence clinically significant bleeding , know coagulopathy . Patients currently warfarin , elevate INR ≥ 1.5 . Patients currently within previous 48 hr . heparin elevate aPTT great upper limit normal . Heparin flush require IV line . Line flush saline . History ICH significant bleeding episode within 3 month study enrollment . Major surgery serious trauma within last 6 week . Patients arterial puncture noncompressible site , biopsy parenchymal organ , lumbar puncture within last 2 week . Previous stroke , myocardial infarction , post myocardial infarction pericarditis , intracranial surgery , significant head trauma within 3 month baseline . Uncontrolled hypertension . Alcohol and/or substance abuse would increase risk hemorrhage opinion investigator . Surgical intervention anticipate within next 7 day . Hepatic dysfunction , define liver function test great 3 time upper limit normal baseline , specifically serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamicpyruvic transaminase ( SGPT ) . Abnormal blood glucose History primary metastatic brain tumor . Severe mental deficit prior onset stroke organic brain disorder , schizophrenia , etc . Concurrent severe neurologic disorder , seizure onset stroke uncontrolled seizure disorder complicate diagnosis acute ischemic stroke . Current platelet count &lt; 100,000/mm3 . Life expectancy &lt; 3 month opinion investigator . Need concomitant ( i.e , Argatroban infusion ) anticoagulants Argatroban , include form heparin , unfractionated heparin ( UFH ) , low molecular weight heparin ( LMWH ) , defibrinogenating agent , dextran , direct thrombin inhibitor thrombolytic agent , glycoprotein llb/llla ( GPIIb/IIIa ) warfarin . ( Caveat : If anticoagulant defer 48 hour , include ) . Participated investigational study within 30 day first dose study medication . Hypersensitivity Argatroban agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>stroke</keyword>
	<keyword>thrombin inhibition</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>bleeding</keyword>
	<keyword>outcome</keyword>
</DOC>